查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924997

全球移植诊断市场预测至2032年：按检测类型、生物标记类型、移植类型、应用、最终用户和地区划分

Transplant Diagnostics Market Forecasts to 2032 - Global Analysis By Test Type (Molecular Assays, Non-Molecular Assays, and Sequencing-based Molecular Assays), Biomarker Type, Transplant Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计 2025 年全球移植诊断市场规模将达到 69.9 亿美元，到 2032 年将达到 131.1 亿美元，预测期内复合年增长率为 9.4%。

移植诊断是一个专注于检测和监测移植器官和组织健康状况及相容性的医学领域。这包括确认捐赠者与受体相容性的检测、追踪器官功能以及及早识别潜在的排斥反应和感染疾病。透过准确快速的评估，该领域帮助医疗服务提供者改善患者预后、延长移植器官寿命并最大限度地减少併发症。

根据美国卫生资源与服务管理局 (HRSA) 的数据，截至 2024 年 3 月，美国已进行了超过 46,000 例器官移植手术。

慢性病发生率呈上升趋势

医疗机构正在寻求先进的检测方法，以优化供体与受体的匹配，并改善患者预后。分子和免疫学检测技术的创新使得移植併发症的早期发现成为可能。人口老化和合併症发生率的上升，凸显了移植后诊断监测的必要性。医院和专科诊所正在部署尖端的诊断平台，以降低排斥反应的风险。个人化医疗的进步推动了为每位患者客製化诊断方案的应用。总体而言，慢性病盛行率的快速成长正在加速先进移植诊断解决方案的普及应用。

器官短缺缺口

器官供应有限给诊断流程带来了越来越大的压力，而提高移植成功率至关重要。监管障碍和严格的伦理准则进一步加剧了捐赠者配对过程的复杂性。资源限制往往限制新兴市场小规模实验室和机构采用先进检测方法。新诊断试剂盒漫长的核准流程也延缓了其临床应用。儘管临床需求迫切，但这些限制因素可能会阻碍对创新技术的投资。因此，器官供需之间的差距持续限制移植诊断市场的扩张。

人工智慧和机器学习

预测演算法可以增强供体-受体相容性评估并预测移植存活率。自动化数据分析可减少诊断错误，并加快移植中心的决策速度。机器学习模型正越来越多地应用于解读复杂的免疫学和基因组资料集。人工智慧驱动平台的应用使检查室能够在提高效率的同时降低营运成本。基于云端的分析有助于跨多个机构对移植患者进行即时监测。预计这一趋势将透过实现精准医疗和预测性护理解决方案，彻底改变移植诊断方式。

伦理和资料隐私问题

处理敏感的基因组和免疫学资讯需要严格遵守资料保护条例。滥用或洩露健康资料可能会损害公众对诊断服务的信任。关于捐赠者知情同意和器官分配的伦理争议可能会影响市场接受度。区域监管差异给跨国诊断服务提供者带来了复杂的挑战。安全的资料储存和遵守隐私标准会增加营运成本。这些因素可能会减缓某些市场对先进移植诊断技术的采用。

新冠疫情的感染疾病：

检查室运作面临临时关闭和人员短缺，影响了检体处理。诊断剂和试剂盒的全球供应链中断，限制了检测的可用性。远端医疗和远端监测被迅速采用，以维持患者随访和移植后护理。监管机构加快了关键诊断工具的核准，以支援紧急情况。此次危机凸显了建构具有韧性的供应链和分散式检查网路的重要性。疫情后，移植诊断正着力于自动化、快速侦测和营运柔软性，以防止未来再次中断。

预测期内，分子检测领域将占据最大的市场份额。

由于分子检测在检测移植相关併发症具有高灵敏度和特异性，因此预计在预测期内，分子检测领域将占据最大的市场份额。这些检测广泛用于监测病毒感染、移植物排斥反应和免疫反应。多重PCR和次世代定序等技术进步拓展了其临床效用。检查室越来越多地采用分子检测平台以加快检测结果的周转速度。这种趋势的动力源自于人们对早期疗育对移植患者益处的认识不断提高。

在预测期内，参考实验室细分市场将实现最高的复合年增长率。

由于其高通量和专业化的检测能力，预计参考实验室领域在预测期内将实现最高成长率。这些机构提供小规模医院难以提供的先进诊断服务。对自动化平台和人工智慧辅助解读的投资有助于提高效率和准确性。将诊断检测外包给参考实验室可以减轻移植中心的营运负担。对复杂免疫学和基因组学检测需求的不断增长正在推动该领域的扩张。参考实验室也正在扩大其全球企业发展，以满足新兴市场的需求。

占比最大的地区：

由于北美拥有先进的医疗基础设施和对创新诊断技术的积极应用，预计在预测期内将占据最大的市场份额。美国和加拿大拥有完善的移植网路和专业实验室。人们对器官移植排斥风险的高度重视推动了检测需求的成长。研发投入和监管支持促进了新型检测方法的开发和商业化。学术机构与诊断公司之间的策略合作也十分普遍。该地区受益于健全的健保报销体系，这鼓励了诊断技术的广泛应用。

预计年复合成长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这主要得益于医疗基础设施的不断改进和器官移植项目的日益增加。中国、印度和日本等国家正大力投资建造现代化实验室和诊断技术。慢性病发病率的上升和人们对移植监测意识提升，推动了市场需求的成长。政府主导的措施正在支持本地生产和技术转移。国际合作使得先进的分子和免疫学检测技术得以应用。人工智慧诊断平台的快速普及提高了检测的准确性。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要企业SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，对主要国家进行市场估算和预测，并计算复合年增长率（註：可行性需确认）。
  • 竞争标竿分析
    • 基于产品系列、地域覆盖范围和策略联盟对主要参与者进行基准分析

目录

第一章执行摘要

第二章 前言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球移植诊断市场（依检测类型划分）

  • 分子检测
    • 基于PCR的检测
    • 即时PCR
    • 次世代定序（NGS）
    • 桑格定序
  • 非分子检测
    • 血清学检测
    • 混合淋巴球培养
  • 基于定序的分子检测

6. 全球移植诊断市场（依生物标记类型划分）

  • 装置
  • 基因生物标誌物
  • 蛋白质体学生物标誌物
  • 细胞生物标记
  • 代谢体学物标誌物

7. 全球移植诊断市场（依移植类型划分）

  • 肾臟移植
  • 肝臟移植
  • 心臟移植
  • 肺移植
  • 骨髓移植
  • 其他的

8. 全球移植诊断市场（按应用划分）

  • 人类白血球抗原（HLA）检测
  • 血液检查
  • 病原体检测
  • 交叉配对试验
  • 其他的

9. 全球移植诊断市场（以最终用户划分）

  • 医院和诊所
  • 诊断检查室
  • 研究和学术机构
  • 参考检查室
  • 其他的

第十章 全球移植诊断市场（按地区划分）

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Illumina, Inc.
  • QIAGEN NV
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Immucor, Inc.
  • CareDx, Inc.
  • Omixon Inc.
  • Hologic, Inc.
  • Adaptive Biotechnologies Corporation
  • NanoString Technologies, Inc.
  • Eurofins Viracor
  • GenDx
Product Code: SMRC33391

According to Stratistics MRC, the Global Transplant Diagnostics Market is accounted for $6.99 billion in 2025 and is expected to reach $13.11 billion by 2032 growing at a CAGR of 9.4% during the forecast period. Transplant diagnostics is a medical discipline focused on examining and monitoring the health and compatibility of transplanted organs or tissues. It encompasses testing to ensure donor-recipient matching, tracking organ functionality, and identifying potential rejection or infections at an early stage. Through precise and prompt assessments, this field assists healthcare providers in enhancing patient outcomes, prolonging graft longevity, and minimizing complications.

According to the Health Resources & Services Administration (HRSA), as of March 2024, more than 46,000 organ transplants were performed in the U.S.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Healthcare providers are seeking precise testing methods to optimize donor-recipient matching and improve patient outcomes. Innovations in molecular and immunological assays are allowing earlier detection of transplant complications. Aging populations and rising comorbidity rates are expanding the need for diagnostic monitoring post-transplant. Hospitals and specialized clinics are adopting cutting-edge diagnostic platforms to reduce rejection risks. The growth of personalized medicine is encouraging the use of tailored diagnostic panels for each patient. Overall, the surge in chronic disease prevalence is accelerating the adoption of sophisticated transplant diagnostic solutions.

Restraint:

Organ shortage gap

Limited organ availability increases the pressure on diagnostic workflows to maximize graft success. Regulatory hurdles and strict ethical guidelines further complicate donor matching processes. Small laboratories and emerging market facilities often face resource constraints that restrict adoption of advanced tests. Prolonged approval timelines for new diagnostic kits delay clinical implementation. These limitations may hinder investment in innovative technologies despite clinical need. As a result, the organ supply-demand gap continues to restrain the expansion of the transplant diagnostics market.

Opportunity:

AI and machine learning

Predictive algorithms can enhance donor-recipient compatibility assessments and forecast graft survival. Automated data analysis reduces diagnostic errors and accelerates decision-making in transplant centers. Machine learning models are increasingly applied to interpret complex immunological and genomic datasets. Adoption of AI-driven platforms allows laboratories to improve efficiency while reducing operational costs. Cloud-based analytics facilitate real-time monitoring of transplant patients across multiple facilities. This trend is expected to transform transplant diagnostics by enabling precision medicine and predictive care solutions.

Threat:

Ethical & data privacy concerns

The handling of sensitive genomic and immunological information requires strict compliance with data protection regulations. Misuse or breaches of health data could erode trust in diagnostic services. Ethical debates around donor consent and organ allocation may affect market acceptance. Regulatory differences across regions create complexities for multinational diagnostic providers. Ensuring secure data storage and adherence to privacy standards increases operational costs. These concerns could slow the adoption of advanced transplant diagnostic technologies in some markets.

Covid-19 Impact:

Laboratory operations faced temporary closures and staffing shortages, affecting sample processing. Global supply chains for diagnostic reagents and kits experienced interruptions, limiting test availability. Telemedicine and remote monitoring were rapidly adopted to maintain patient follow-up and post-transplant care. Regulatory authorities introduced expedited approvals for critical diagnostic tools to support urgent cases. The crisis highlighted the need for resilient supply chains and decentralized laboratory networks. Post-pandemic, transplant diagnostics are focusing on automation, rapid testing, and operational flexibility to prevent future disruptions.

The molecular assays segment is expected to be the largest during the forecast period

The molecular assays segment is expected to account for the largest market share during the forecast period, due to their high sensitivity and specificity in detecting transplant-related complications. These assays are widely used for monitoring viral infections, graft rejection, and immune response. Technological advancements, such as multiplex PCR and next-generation sequencing, are expanding their clinical utility. Laboratories are increasingly implementing molecular platforms for faster turnaround times. Adoption is driven by growing awareness of early intervention benefits for transplant patients.

The reference labs segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the reference labs segment is predicted to witness the highest growth rate, due to their capacity for high-throughput and specialized testing. These facilities provide advanced diagnostic services that smaller hospitals may lack. Investments in automated platforms and AI-assisted interpretation improve efficiency and accuracy. Outsourcing diagnostic testing to reference labs reduces operational burdens for transplant centers. Rising demand for complex immunological and genomic testing is driving expansion. Reference labs are also expanding their global footprint to cater to emerging markets.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its advanced healthcare infrastructure and strong adoption of innovative diagnostics. The U.S. and Canada have well-established transplant networks and specialized laboratories. High awareness of organ rejection risks is driving demand for sophisticated testing. Investment in R&D and regulatory support encourage development and commercialization of new assays. Strategic collaborations between academic centers and diagnostic companies are common. The region benefits from robust reimbursement frameworks that facilitate widespread diagnostic adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure and increasing organ transplant programs. Countries like China, India, and Japan are investing heavily in modern laboratories and diagnostic technologies. Growing incidence of chronic diseases and rising awareness of transplant monitoring is boosting demand. Government initiatives are supporting local manufacturing and technology transfer. International collaborations are enabling access to advanced molecular and immunological assays. Rapid adoption of AI-enabled diagnostic platforms is enhancing testing accuracy.

Key players in the market

Some of the key players in Transplant Diagnostics Market include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Illumina, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Immucor, Inc., CareDx, Inc., Omixon Inc., Hologic, Inc., Adaptive Biotechnologies Corporation, NanoString Technologies, Inc., Eurofins Viracor, and GenDx.

Key Developments:

In January 2026, Thermo Fisher Scientific Inc. announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence (AI) platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories. The companies are working together to evolve the digital foundation that powers scientific instruments, laboratory infrastructure and data.

In January 2026, Abbott announced a collaboration with AtaCor Medical to advance a next-generation investigational extravascular implantable cardioverter defibrillator (EV-ICD) system designed to deliver defibrillation therapy to people with life-threatening heart rhythms. Through the collaboration, AtaCor's investigational parasternal EV-ICD lead (Atala(TM)) will be paired with Abbott's investigational ICD system.

Test Types Covered:

  • Molecular Assays
  • Non-Molecular Assays
  • Sequencing-based Molecular Assays

Biomarker Types Covered:

  • Instruments
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Cellular Biomarkers
  • Metabolomic Biomarkers

Transplant Types Covered:

  • Kidney Transplant
  • Liver Transplant
  • Heart Transplant
  • Lung Transplant
  • Bone Marrow Transplant
  • Other Organ Transplants

Applications Covered:

  • Human Leukocyte Antigen (HLA) Testing
  • Blood Profile Testing
  • Pathogen Detection
  • Crossmatching
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutes
  • Reference Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Transplant Diagnostics Market, By Test Type

  • 5.1 Introduction
  • 5.2 Molecular Assays
    • 5.2.1 PCR-based assays
    • 5.2.2 Real-time PCR
    • 5.2.3 Next-Generation Sequencing (NGS)
    • 5.2.4 Sanger Sequencing
  • 5.3 Non-Molecular Assays
    • 5.3.1 Serological Assays
    • 5.3.2 Mixed Lymphocyte Culture
  • 5.4 Sequencing-based Molecular Assays

6 Global Transplant Diagnostics Market, By Biomarker Type

  • 6.1 Introduction
  • 6.2 Instruments
  • 6.3 Genomic Biomarkers
  • 6.4 Proteomic Biomarkers
  • 6.5 Cellular Biomarkers
  • 6.6 Metabolomic Biomarkers

7 Global Transplant Diagnostics Market, By Transplant Type

  • 7.1 Introduction
  • 7.2 Kidney Transplant
  • 7.3 Liver Transplant
  • 7.4 Heart Transplant
  • 7.5 Lung Transplant
  • 7.6 Bone Marrow Transplant
  • 7.7 Other Organ Transplants

8 Global Transplant Diagnostics Market, By Application

  • 8.1 Introduction
  • 8.2 Human Leukocyte Antigen (HLA) Testing
  • 8.3 Blood Profile Testing
  • 8.4 Pathogen Detection
  • 8.5 Crossmatching
  • 8.6 Other Applications

9 Global Transplant Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Research & Academic Institutes
  • 9.5 Reference Labs
  • 9.6 Other End Users

10 Global Transplant Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific, Inc.
  • 12.2 F. Hoffmann-La Roche Ltd.
  • 12.3 Abbott Laboratories
  • 12.4 Illumina, Inc.
  • 12.5 QIAGEN N.V.
  • 12.6 Bio-Rad Laboratories, Inc.
  • 12.7 Becton, Dickinson and Company
  • 12.8 Immucor, Inc.
  • 12.9 CareDx, Inc.
  • 12.10 Omixon Inc.
  • 12.11 Hologic, Inc.
  • 12.12 Adaptive Biotechnologies Corporation
  • 12.13 NanoString Technologies, Inc.
  • 12.14 Eurofins Viracor
  • 12.15 GenDx

List of Tables

  • Table 1 Global Transplant Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Transplant Diagnostics Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 3 Global Transplant Diagnostics Market Outlook, By Molecular Assays (2024-2032) ($MN)
  • Table 4 Global Transplant Diagnostics Market Outlook, By PCR-based assays (2024-2032) ($MN)
  • Table 5 Global Transplant Diagnostics Market Outlook, By Real-time PCR (2024-2032) ($MN)
  • Table 6 Global Transplant Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 7 Global Transplant Diagnostics Market Outlook, By Sanger Sequencing (2024-2032) ($MN)
  • Table 8 Global Transplant Diagnostics Market Outlook, By Non-Molecular Assays (2024-2032) ($MN)
  • Table 9 Global Transplant Diagnostics Market Outlook, By Serological Assays (2024-2032) ($MN)
  • Table 10 Global Transplant Diagnostics Market Outlook, By Mixed Lymphocyte Culture (2024-2032) ($MN)
  • Table 11 Global Transplant Diagnostics Market Outlook, By Sequencing-based Molecular Assays (2024-2032) ($MN)
  • Table 12 Global Transplant Diagnostics Market Outlook, By Biomarker Type (2024-2032) ($MN)
  • Table 13 Global Transplant Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 14 Global Transplant Diagnostics Market Outlook, By Genomic Biomarkers (2024-2032) ($MN)
  • Table 15 Global Transplant Diagnostics Market Outlook, By Proteomic Biomarkers (2024-2032) ($MN)
  • Table 16 Global Transplant Diagnostics Market Outlook, By Cellular Biomarkers (2024-2032) ($MN)
  • Table 17 Global Transplant Diagnostics Market Outlook, By Metabolomic Biomarkers (2024-2032) ($MN)
  • Table 18 Global Transplant Diagnostics Market Outlook, By Transplant Type (2024-2032) ($MN)
  • Table 19 Global Transplant Diagnostics Market Outlook, By Kidney Transplant (2024-2032) ($MN)
  • Table 20 Global Transplant Diagnostics Market Outlook, By Liver Transplant (2024-2032) ($MN)
  • Table 21 Global Transplant Diagnostics Market Outlook, By Heart Transplant (2024-2032) ($MN)
  • Table 22 Global Transplant Diagnostics Market Outlook, By Lung Transplant (2024-2032) ($MN)
  • Table 23 Global Transplant Diagnostics Market Outlook, By Bone Marrow Transplant (2024-2032) ($MN)
  • Table 24 Global Transplant Diagnostics Market Outlook, By Other Organ Transplants (2024-2032) ($MN)
  • Table 25 Global Transplant Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 26 Global Transplant Diagnostics Market Outlook, By Human Leukocyte Antigen (HLA) Testing (2024-2032) ($MN)
  • Table 27 Global Transplant Diagnostics Market Outlook, By Blood Profile Testing (2024-2032) ($MN)
  • Table 28 Global Transplant Diagnostics Market Outlook, By Pathogen Detection (2024-2032) ($MN)
  • Table 29 Global Transplant Diagnostics Market Outlook, By Crossmatching (2024-2032) ($MN)
  • Table 30 Global Transplant Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 31 Global Transplant Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Transplant Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 33 Global Transplant Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Transplant Diagnostics Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 35 Global Transplant Diagnostics Market Outlook, By Reference Labs (2024-2032) ($MN)
  • Table 36 Global Transplant Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.